Clinical Question Among patients at high risk for or with established cardiovascular disease
(ie, history of peripheral artery disease, stroke, or coronary artery disease without a coronary …

BACKGROUND: Clopidogrel is a more potent antiplatelet agent than aspirin, resulting in
greater clinical efficacy in patients with atherothrombotic disease. Furthermore, the …

Atherothrombosis is the most common cause of an acute ischemic event. Antiplatelet agents
form the cornerstone of atherothrombosis prevention. The purpose of this article is to review …

Antiplatelet agents are central to the treatment and prevention of cardiovascular disease.
Although aspirin is the most widely used agent, randomized trials have assessed whether …

Background Dual antiplatelet therapy with clopidogrel plus low-dose aspirin has not been
studied in a broad population of patients at high risk for atherothrombotic events. Methods …

Background Aspirin is the prophylactic antiplatelet drug of choice for people with
cardiovascular disease. Adding a second antiplatelet drug to aspirin may produce additional …

The results of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization,
Management and Avoidance (CHARISMA) trial showed that the addition of clopidogrel to …

Clopidogrel plus aspirin did not differ from aspirin alone for reducing MI, stroke, and CV death
in high risk atherothrombosis. - Abstract - Europe PMC Sign in | Create an account …

Objectives To quantify the impact of clopidogrel plus aspirin on the individual outcomes of
death, myocardial infarction, or stroke in patients with established cardiovascular disease, or …

According to the World Health Organization, car-diovascular diseases caused 16.6 million
deaths worldwide (29.3% of all deaths) in 2001. Coronary heart disease was the leading …